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ABSTRACT
Acute and Repeated Effects of Synthetic Cannabinoid Agonism and Cannabinoid Receptor 1
Positive Allosteric Modulation
Kristen R. Trexler

Recent years have seen a rise in the diversity and use of synthetic cannabinoids.
Currently, there is little known about the effects of specific synthetic cannabinoid compounds.
As such, little research has been done evaluating the acute and chronic effects of synthetic
cannabinoid administration or the development of tolerance and withdrawal. The present study
aimed, in part, to evaluate the acute and repeated effect of a third-generation synthetic
cannabinoid, AB-FUBINACA. Mice were treated with AB-FUBINACA (0.1-3 mg/kg, i.p.) or
vehicle and were tested repeatedly in the tetrad battery of assays, which included tests of
catalepsy, antinociception, hypothermia, and locomotor activity. A second group of mice was
injected with AB-FUBINACA (3 mg/kg, s.c.) twice daily for 6 days and were tested daily in
tetrad. On the 6th day, withdrawal was precipitated using the cannabinoid receptor antagonist
rimonabant (3 mg/kg), and behavior was scored in the somatic signs of withdrawal tests. ABFUBINACA exhibited classic acute cannabinoid effects in the tetrad but showed a lack of
tolerance and cross-tolerance to THC (50 mg/kg, i.p.). Further, precipitated withdrawal from
AB-FUBINACA was of a much smaller magnitude than what is typical of other phyto- and
synthetic cannabinoids.
Another aspect of cannabinoid research that has been largely overlooked is the use of
assays that are able to detect spontaneous (i.e., abstinence-induced) withdrawal. Previous
research has demonstrated that spontaneous withdrawal can be detected with certain assays, like
the somatic signs of withdrawal and tail suspension tests. To determine whether an anhedonia
test would detect signs of spontaneous withdrawal, mice were trained to consume a sweetened
condensed milk mixture over 9 days. During the final 6 days of training, mice were injected
twice daily with THC (10 or 50 mg/kg, s.c.) or vehicle. On the 9 th day, injections were stopped
and mice were tested again at 12h and 36h abstinence. No changes were observed as a result of
spontaneous withdrawal from THC.
Despite recent increases in attention to cannabinoid use disorders, there remains a need
for pharmacological interventions. ZCZ011 is a CB1 positive allosteric modulator that increases
the effect of CB1 agonists bound at the orthosteric site. We hypothesized that ZCZ011
significantly attenuates behavioral signs of cannabinoid withdrawal. Mice were administered ∆9THC (10 mg/kg, b.i.d., s.c.) or vehicle for six days, then withdrawal was precipitated using
rimonabant (3 mg/kg, i.p.). As previously reported, ∆9-THC withdrawal induced paw tremors
and head twitches. Acute ZCZ011 (≥10 mg/kg, i.p.) significantly attenuated paw tremors and
head twitches. ZCZ011 (≥10 mg/kg, i.p.) was also administered to mice subjected to spontaneous
THC withdrawal. ZCZ011 reduced spontaneous THC withdrawal-induced head twitches and
paw tremors. An additional group of mice was injected with ZCZ011 (10 mg/kg, i.p.) or one of
its enantiomers, ZCZ011 A or ZCZ011 B prior to precipitated THC withdrawal. Both ZCZ011
10 mg/kg or either enantiomer alone attenuated paw tremors and head twitches.
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1. Introduction
1.1 Endocannabinoid system
Cannabinoids are molecules that (1) bind to and activate the cannabinoid (CB) receptors,
or (2) share structural homology with known CB receptor ligands (Mechoulam & Parker, 2012).
There are two cannabinoid G-protein coupled receptors, i.e., Cannabinoid receptor subtype 1
(CB1) and Cannabinoid receptor subtype 2 (CB2), that affect intracellular signaling through the
inhibition of adenylate cyclase (Howlett, 1985). CB1 is expressed primarily in the central
nervous system, on GABAergic and glutamatergic neurons (Jacob et al., 2009; Steiner &
Wotjak, 2008), whereas CB2 is expressed primarily in the periphery and also commonly
expressed on glial cells and in the brainstem (Finn, 2010). CB1 agonism is associated with
psychoactive effects, including mild euphoria, relaxation, motor function disruption, and
analgesia, typically reported during cannabis use. Conversely, CB2 is implicated in antiinflammatory and immunosuppressive effects that contribute to analgesia, which is a decrease in
pain response (Lombard, Nagarkatti, & Nagarkatti, 2007). Both exogenous (i.e., externally
administered) and endogenous (i.e., internally produced) cannabinoids bind to CB1 and CB2
receptors with moderate to high affinity (Lombard et al., 2007; Singh et al., 2012).
Activation of cannabinoid receptors leads to inhibition of adenylyl cyclase and the
activation of mitogen-activated protein kinases, which ultimately cause inhibition of responses to
stimuli that would normally depolarize the cell, and can decrease neurotransmitter release.
(Freund, Katona, & Piomelli, 2003; Howlett, 2005; Mackie, 2008). Simultaneously, cannabinoid
receptor activation closes N- and P/Q-type calcium (Ca2+) ion channels (Flores, Maldonado, &
Berrendero, 2013; Steiner & Wotjak, 2008), and, due to freed Gβ/γ subunits and reduced cAMP,
inward rectifying potassium (K+) channels are also activated (Deadwyler, Hampson, Mu, Whyte,
& Childers, 1995; Mu, Zhuang, Kirby, Hampson, & Deadwyler, 1999). Together, these effects
contribute to hyperpolarization of the presynaptic neuron, which inhibits neurotransmitter release
and decreases excitatory post-synaptic potentials in the postsynaptic neuron.
1.1.1 Phytocannabinoids
Phytocannabinoids are compounds derived from the Cannabis plant. Over 60 different
cannabinoids have been identified in cannabis, including the well-known and most tested Δ9tetrahydrocanabinol (THC) (Gaoni & Mechoulam, 1964). In addition to mild euphoria, THC can
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cause cognitive deficits, such as memory loss and altered time perception (Mechoulam & Parker,
2012; Morgan, Schafer, Freeman, & Curran, 2010).
1.1.2 Endocannabinoids
Endogenously produced cannabinoids (i.e., endocannabinoids) are produced in humans
and are evolutionarily well preserved across vertebrates (Fisar, 2009). The two well-established
endocannabinoids are 2-arachidonoyl glycerol (2-AG) and N-arachydonoylethanolamine, which
is also known as anandamide for the Sanskrit word “ananda” meaning “bliss” (Devane et al.,
1992; Mechoulam et al., 1995). Endocannabinoid levels are comparable in most tissues except in
the brain, where 2-AG is present in 100-fold higher levels than anandamide (Long et al., 2009).
Both endocannabinoids bind to and activate CB1 and CB2 (Lu & MacKie, 2016; Mechoulam &
Parker, 2012). Unlike neurotransmitters that are produced in the endoplasmic reticulum and
stored in vesicles, endocannabinoids are synthesized de novo from lipid precursors, and rapidly
released on demand.
Endocannabinoid metabolism is tightly regulated by synthetic and catabolic enzymes.
Although there is some controversy, a generally accepted synthetic pathway uses NArachidonoyl-phosphatidylethanolamine specific phospholipase D (PLD) and phospholipase C
(PLC) to convert N-Arachidonoyl-phosphatidylethanolamine (NArPE) into anandamide. 2-AG
synthesis is more clearly delineated. 2-AG synthesis is more clearly delineated. Diacylglycerols
(DAGs) are synthesized by diacylglycerol lipases α and β into 2-AG (Di Marzo, 2009; Flores,
Maldonado, & Berrendero, 2013; Howlett, 2005). Anandamide is primarily catabolized by fatty
acid amide hydrolase (FAAH) while 2-AG is primarily catabolized by monoacylglycerol lipase
(MAGL), and the remaining ~15% is catabolized by the enzymes ABHD6, ABHD12, and
cyclooxygenase (Blankman, Simon, & Cravatt, 2007; Cravatt et al., 1996; McKinney & Cravatt,
2005). Chemical inhibition or genetic deletion of either FAAH or MAGL selectively increases
anandamide or 2-AG levels, respectively. Enzymatic regulation of endocannabinoids by FAAH
and MAGL is extremely efficient, effectively nullifying the exogenous administration of
endocannabinoids. Thus, to study effects of the endocannabinoids in vivo, several compounds
have been synthesized that act to selectively inhibit the activity of these catabolic enzymes,
thereby indirectly increasing brain levels of anandamide or 2-AG.
1.1.3 Synthetic cannabinoids
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The term “synthetic cannabinoid” technically refers to any lab-produced compound that
affects CB1 or CB2 function and includes receptor agonists and antagonists, inhibitors of
enzymes mentioned in the previous paragraph, as well as allosteric modulators, which are
detailed in section 1.4 (Hess, Schoeder, Pillaiyar, Madea, & Müller, 2016). Colloquially,
"synthetic cannabinoid" refers to a CB1 or CB2 agonist, and for the remainder of this document
such compounds will be referred to as synthetic cannabinoids. These compounds were originally
synthesized for research purposes, such as receptor/ligand interaction studies, or to selectively
agonize one receptor without affecting the other (Banister, Moir, et al., 2015; Banister, Stuart, et
al., 2015; Huffman et al., 2005). Once the chemical structures of synthetic cannabinoids were
published, clandestine chemists hijacked the compounds and produced so-called “safe”
alternatives to cannabis (Jarbe & Raghav, 2016).
Though some individuals ingest powdered forms of synthetic cannabinoids, the most
common route of administration is inhalation of smoked or vaporized plant material treated with
one or more of the synthetic cannabinoids (Seely, Lapoint, Moran, & Fattore, 2012). Solutions of
one or more synthetic cannabinoids, in a solvent, are often sprayed onto inert plant material,
including blue and pink lotus, skull caps, or rose hips, but may also be applied to plant material
containing psychoactive alkaloids (de Havenon, Chin, Thomas, & Afra, 2011; Dresen et al.,
2010; EMCDDA, 2009; Seely et al., 2012). Sold under the broad umbrella term “Spice,” these
synthetic cannabinoid preparations are labeled "not for human consumption" to avoid regulation
by the Food and Drug Administration (Brents, Zimmerman, Saffell, Prather, & Fantegrossi,
2013), despite their true intended use.
Synthetic cannabinoids are broadly categorized into 7 families, based on chemical
structure: cyclohexyl-substituted phenols (e.g., CP 47,497), naphtholindoles (e.g., AM-2201,
JWH-018), benzoylindoles (e.g., 6 APB), tetramethylcyclopropylindoles (e.g.,UR-144, XLR 11),
adamantoylindoles (e.g., AKB48), indazole carboxamides (e.g.,AB-FUBINACA, AB-PINACA),
and quinolinyl esters (e.g., PB22) (Canazza et al., 2016; Ford, Tai, Fantegrossi, & Prather, 2017;
Hess et al., 2016). Though their structures differ, many synthetic cannabinoids act as full
agonists at CB1, and in some cases CB2 (Fantegrossi, Moran, Radominska-pandya, & Prather,
2014; Ford et al., 2017; Hess et al., 2016). Whereas THC is a partial agonist of CB1 and CB2,
synthetic cannabinoids often have a relatively lower Ki value, indicating higher binding affinity,
and thus synthetic cannabinoids induce similar cannabimimetic effects to THC, but at relatively
3
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lower doses (Hess et al., 2016; Wiley et al., 2015). In the “tetrad” battery of cannabinoid
behavioral and physiological effects, both first generation (e.g., JWH-018, CP55,940) and later
generation (e.g., AB-FUBINACA, AB-CHMINACA) synthetic cannabinoids induce catalepsy,
antinociception, and hypothermia in mice (Paronis, Nikas, Shukla, & Makriyannis, 2012; Wiley
et al., 2015). See Table 1 for examples of generational structure differences. Unlike THC, which
has dose-dependent sedative effects in rodents, synthetic cannabinoids have inconsistent effects
on locomotor activity. For instance, acute high and low dose AB-FUBINACA administration
decreased locomotor activity in rats in one study (Kevin et al., 2017), but only high doses
induced immobility in two other studies that used mice (Gatch & Forster, 2015; Schreiber et al.,
2018).
Table 1. Structures of representative synthetic cannabinoids by generation.
Generation
First

Second

Third

Compound
WIN55-212

Structure

Source
Banister, Stuart,
et al., 2015

CP55,940

Hess et al., 2016

JWH-018

Canazza et al.,
2016

AM2201

Carlier et al.,
2018

6 APB

Chan, Wood,
Hudson, &
Dargan, 2013
Castaneto et al.,
2014

AB-FUBINACA
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AKB48

Canazza et al.,
2016

5F-PB-22

Diao et al., 2016

While there are many issues associated with human synthetic cannabinoid use, one of the
primary concerns is their ever-increasing diversity and the lack of regulation surrounding their
creation and distribution. As of 2015, 160 independent synthetic cannabinoid compounds have
been identified in samples obtained from shops and over the internet (EMCDDA 2016).
Research into synthetic cannabinoids has expanded from exploring primarily pharmacological
and behavioral outcomes to include studies of routes of administration, metabolism, and human
patterns of synthetic cannabinoid use (Banister, Moir, et al., 2015; Chase et al., 2016; Fantegrossi
et al., 2014; Lefever et al., 2017; Su, Seely, Moran, & Hoffman, 2015; Wiebelhaus et al., 2012).
Though many synthetic cannabinoids are assumed to have abuse potential, little work has
evaluated the development of tolerance and withdrawal of the newest families of cannabinoids.
Further, much of the research done using synthetic cannabinoids rely primarily on physiological
and gross behavioral outcomes (Banister, Moir, et al., 2015; Gatch & Forster, 2015; Kevin et al.,
2017), with little attention given to dependence and withdrawal effects.

1.1.3.1 AB-FUBINACA
AB-FUBINACA is a member of the indazole carboxamide family of synthetic
cannabinoids that also includes AB-CHMINACA and AB-PINACA, both of which have been
linked to deaths in the United States (Trecki, Gerona, & Schwartz, 2015). AMB-FUBINACA
was responsible for a recent series of overdoses in Connecticut. In August of 2018 at least 71
people presented to emergency services with loss of consciousness, vomiting and nausea, and
lethargy but displayed no physiological abnormalities (https://www.cbsnews.com/news/newhaven-overdoses-connecticut-new-haven-green-k2-synthetic-marijuana). This absence of AMBFUBINACA induced physiological effects is unusual, as most synthetic cannabinoids induce
5

Synthetic Cannabinoid Agonism and Positive Allosteric Modulation - Trexler
tachycardia, bradycardia, and/or elevated blood pressure in humans (Chinnadurai, Shrestha, &
Ayinla, 2016; Davidson et al., 2017; Mir, Obafemi, Young, & Kane, 2011). In contrast, ABFUBINACA induces bradycardia in rats (Banister, Moir, et al., 2015). This interspecific
difference is likely due to differences in dosing, or perhaps metabolism.
AB-FUBINACA is one of the better characterized of the new generation of indazole
carboxamide synthetic cannabinoids. AB-FUBINACA induces hypothermia and decreases
locomotor activity in both mice (Schreiber et al., 2018) and rats (Banister, Moir, et al., 2015;
Kevin et al., 2017) and does not affect nociception in mice (Schreiber et al., 2018) although the
lack of antinociception has not been probed in rats. It is somewhat surprising that no data are
available on AB-FUBINACA effects on catalepsy, given that catalepsy is a classic cannabinoid
effect (Wiley et al., 2015). In a drug discrimination task, AB-FUBINACA fully substitutes for
THC, although it also depresses response rate, with incomplete cross-tolerance between the two
cannabinoids (Gatch & Forster, 2015).
Cannabinoids have well-established effects on emotion in people, as well as in
experimental animal models. AB-FUBINACA is similar to THC in that it elicits anxiolytic-like
effects in low doses in the elevated plus maze, but it diverges from THC by producing
anxiogenic-like effects in high doses, in mice (Schreiber et al., 2018). In addition, ABFUBINACA decreases struggling in the forced swim test at a low dose (Schreiber et al., 2018),
which is generally indicative of a depressive-like effect, but increases struggling at a high dose,
which is generally interpreted as anti-depressive-like or manic effect.
1.2 Human synthetic cannabinoid use
As mentioned in section 1.1.3, synthetic cannabinoids were initially developed for
therapeutic purposes (Huffman et al., 2005) although many have been hijacked for recreational
use. It is because of this unplanned human use and unpredictable negative effects that synthetic
cannabinoids have gained such recent attention. Yet, it is important to keep in mind that, some
synthetic cannabinoids have proven effective in attenuating disease states. For instance, JWH133, a selective CB2 agonist, and WIN55,212-2, a nonselective CB1 and CB2 agonist, both
inhibit breast tumor growth and metastasis in vitro and in vivo (Olea-Herrero, Vara, MalagarieCazenave, & Díaz-Laviada, 2009; Qamri et al., 2009). The therapeutic use of synthetic
cannabinoids has been severely limited, however, by the presence of side effects in preclinical
models, including abuse potential and seizure (Cooper, 2016; de Havenon et al., 2011; Schaefer
6
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et al., 2013). Thus it is not surprising that, as of October 2018, 1,478 poison control calls
regarding synthetic cannabinoid use have been reported (“American Assoication of Poison
Control Centers: Synthetic Cannabinoids,” 2018). The following sections will focus on the acute
and chronic effects of synthetic cannabinoid administration, with an emphasis on the effects in
humans, because much of the research and literature on these drugs is effectively playing catchup with clinical reports of what is being used.
1.2.1 Acute use
Recreational use of synthetic cannabinoids has increased dramatically in recent years, and
with increased use, there has been a concomitant increase in emergency department visits. Few
assays currently detect synthetic cannabinoids in blood or urine (Islam et al., 2018; Muehlethaler,
Leona, & Lombardi, 2016; Sobolevsky, Prasolov, & Rodchenkov, 2010), an issue that is
compounded by the ever-changing synthetic cannabinoids used in spice compounds. Thus, it has
been difficult to track exactly which synthetic cannabinoid(s) caused a given adverse health
episode. Even determining the dose ingested can be difficult, because the plant materials often
have “hot spots,” as a result of uneven distribution, and high inter- and intra-batch variability in
quality and dose (Frinculescu, Lyall, Ramsey, & Miserez, 2017; Hudson & Ramsey, 2011;
Marshell et al., 2014; van Amsterdam, Brunt, & van den Brink, 2015). Moreover, of the cases
where the compounds involved are known, there is often more than one compound present
(Musshoff et al., 2014). Thus, when evaluating the health outcomes of synthetic cannabinoids,
they are often grouped together, irrespective of drug family. Regardless of this caveat, synthetic
cannabinoids clearly differ from cannabis in their effects.
In humans, acute synthetic cannabinoid use can cause symptoms including: agitation,
anxiety, hallucinations, tachycardia, bradycardia, hypotension, diaphoresis, diarrhea, vomiting,
myocardia ischemia, and rhabdomyolysis (Benford & Caplan, 2011; Besli, Ikiz, Yildirim, &
Saltik, 2015; Bhanushali, Jain, Fatima, Leisch, & Thornley-Brown, 2013; Clark, Georgekutty, &
Berul, 2015; Durand, Delgado, Parra-Pellot, & Nichols-Vinueza, 2015). Several deaths and
serious injuries have been reported following acute synthetic cannabinoid use, including selfmutilation and several suicides, most of which have been attributed to hallucinations (Gay, 2010;
Meijer, Russo, & Adhvaryu, 2014; Patton et al., 2013; Thomas, Kloner, & Rezkalla, 2014;
Trecki et al., 2015). Psychosis induced by synthetic cannabinoid use is so common that some
researchers have proposed referring to it as “spiceophrenia” (Papanti et al., 2013). In a study that
7
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retroactively reviewed emergency room presentations from 16 different locations across Europe,
approximately 15% patients presenting with psychosis reported using synthetic cannabinoid
products (Vallersnes et al., 2016). However, these self-report measures are hampered by the
inability of users to identify which specific drug(s) they may have ingested (again, spice products
do not list ingredients), as well as polydrug use.
The acute hallucinogenic effects of synthetic cannabinoids may be explained by their
indirect effects on dopamine and serotonin, via GABA and glutamate modulation. For example,
JWH-018 increases dopamine in the nucleus accumbens in a manner similar to schizophrenia,
however, this effect is likely achieved by modulating glutamate and GABA, rather than acting
directly on dopamine (El Khoury, Gorgievski, Moutsimilli, Giros, & Tzavara, 2012; Fantegrossi,
Wilson, & Berquist, 2018). Additionally, synthetic cannabinoids can increase the formation of
5HT2A-DA2 heterodimers in the prefrontal cortex in rats, which has been implicated as a possible
mechanism for the positive symptoms of schizophrenia (Franklin & Carrasco, 2012). Thus, the
presence of psychosis and hallucinations may be explained by synthetic cannabinoid interactions
with dopamine and serotonin.
A particularly dangerous, yet poorly understood, side effect of acute synthetic
cannabinoid use is seizure. Seizures induced by synthetic cannabinoid use may occur
immediately (i.e., within minutes of use) or after a delay of several hours or even days (de
Havenon et al., 2011; Schaefer et al., 2013). Although the physiological mechanism(s) are
unknown, it is hypothesized that off-target effects, lack of quality control, toxicity (absence of
mitigating phytocannabinoids and endocannabinoids), ligand bias, or active
metabolites/degradants are likely contributing factors (Chimalakonda et al., 2012; Pertwee,
2009). Further complicating mechanistic studies, the metabolites of many synthetic cannabinoids
are active and bind to and activate CB receptors at similar affinities to the parent compound
(Erratico et al., 2015; Fantegrossi et al., 2014). This is in contrast to THC, which has only one
psychoactive metabolite, 11-OH-THC (Huestis, 2007; Matsuda, Lolait, Brownstein, Young, &
Bonner, 1990).
1.2.2 Chronic use
Little is known about the effects of chronic synthetic cannabinoid administration. One
case report indicates that repeated synthetic cannabinoid use may lead to relatively long-term
psychosis (Durand et al., 2015). It is plausible that 5HT2A receptors mediate the psychogenic
8
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effects of synthetic cannabinoids, because their upregulation in schizophrenia, and following
repeated synthetic cannabinoid use, is mediated through CB1 activation (Fantegrossi et al., 2018).
A more common effect of chronic drug use is dependence. There is evidence, in both preclinical
models and from case reports, that repeated use of synthetic cannabinoids induces tolerance and
dependence, as evidenced by withdrawal following cessation of use (Aceto, Scates, & Martin,
2001; Nacca et al., 2013; Sampson, Bedy, & Carlisle, 2015; Trexler et al., 2018). The potential
for dependence and withdrawal presents a major problem. Currently, cannabis is the most
commonly used federally illicit substance for which individuals seek treatment, and there are few
effective options for its treatment (Substance Use and Mental Health Services Administration,
2015).
1.3 Cannabis Use Disorder
In addition to the acute health risks of cannabis use, such as increased risk of vehicular
accidents (Hartman & Huestis, 2013), chronic use induces varying degrees of dependence. In
clinical populations, cannabis dependence, also referred to as Cannabis Use Disorder (CUD), is
now routinely tracked by health care professionals. Although only 2-6% of users are estimated to
experience some level of CUD, the overall number of people with some level of CUD is
expected to grow as cannabis becomes more widely available (Hasin et al., 2016). CUD is most
often characterized by the presence of withdrawal symptoms following cessation of drug use.
Withdrawal symptoms of CUD vary across individuals, but typically include anxiety,
depression, sleep disturbances, and can include somatic symptoms, including gastric
disturbances and headache (American Psychiatric Association, 2013). The presence of
cannabinoid withdrawal symptoms can lead to relapse after cessation (Budney, Vandrey,
Hughes, Thostenson, & Bursac, 2008; Haney et al., 2013). Cognitive behavioral therapies have
seen modest short-term success in reducing CUD, with only 19-29% of individuals maintaining
abstinence at a 12-month follow up (Budney, Vandrey, Hughes, Moore, & Bahrenburg, 2007;
Ramesh & Haney, 2015). Unlike other commonly abused drugs, like opioids or nicotine, there
are currently no FDA approved pharmacological therapies to relieve cannabinoid withdrawal
symptoms (Allsop, Lintzeris, Copeland, Dunlop, & McGregor, 2015; Mason, Mustafa, Filbey,
Brown, & Mason, 2016).
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Presently, pharmacological treatments for CUD have focused on its symptoms (e.g.,
anxiety and depression) or oral administration of THC. For instance, anti-depressant and antianxiety medications that act on noradrenergic, serotonergic and GABAergic targets have been
used to treat specific aspects of withdrawal, but are not effective in attenuating withdrawal as a
whole (Brezing & Levin, 2017). Several studies have attempted to treat cannabis withdrawal by
administering THC or dronabinol (i.e., synthetically produced Δ9-THC, brand name Marinol),
which were unsuccessful at preventing relapse, but did relieve depression associated with
withdrawal (Haney et al., 2008, 2004). Combinations of cannabinoid and non-cannabinoid
therapies have been effective in attenuating some symptoms of withdrawal, however, they
enhance other symptoms, like withdrawal-induced anorexia and sedation (Haney et al., 2008;
Levin et al., 2016).
The growing popularity of synthetic cannabinoids, coupled with their unpredictably
psychogenic effects, raises concerns about the potential for dependence. Many individuals
initiate synthetic cannabinoid use under the age of 25 and have a previous history of using
cannabis (Monte et al., 2017; Morean, Kong, Camenga, Cavallo, & Krishnan-Sarin, 2015).
Individuals who initiate cannabis use earlier in life are more likely to develop CUD (Budney et
al., 2007). Thus, while the long-term effects of synthetic cannabinoid use are still largely
unknown, case reports indicate that the withdrawal syndrome is similar to withdrawal from
cannabis, but may be more severe, in one case producing multiple seizures on multiple cessation
attempts (Nacca et al., 2013; Sampson et al., 2015). The growing, world-wide use of synthetic
cannabinoids highlights the need for effective pharmacological interventions for cannabinoid
dependence.
1.4 Positive CB1 allosteric modulation
An exciting, recently developed research tool that has shown promise in preclinical
models is CB receptor allosteric modulation. Positive allosteric modulators (PAMs) bind to the
allosteric (i.e., non-orthosteric) sites of receptors, and act to increase the efficacy and/or affinity
of orthosteric ligands (Kenakin, 2013). Because they bind to allosteric site(s), rather than the
orthosteric site, CB1 PAMs represent an alternative approach for treating cannabinoid-related
disorders (Burford, Traynor, & Alt, 2015; Ross, 2007; Figure 1). For example, the synthetic CB1
PAM, GAT211, is antinociceptive in acute mechanical and neuropathic pain models, but does
10
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not elicit cannabimimetic effects in mice (Slivicki et al., 2017). Our own data indicate that the
CB1 PAM ZCZ011 attenuates THC withdrawal, without inducing cannabimimetic side effects,
by increasing efficacy or affinity of endocannabinoids (Trexler, Eckard, & Kinsey, 2019).

The present studies evaluated the behavioral effects of acute and repeated administration
of a new generation of synthetic cannabinoid, AB-FUBINACA, and have evaluated both
ZCZ011 and its enantiomers as therapeutic targets for THC withdrawal. The goals of these
studies were to: 1. evaluate acute and chronic effects of AB-FUBINACA in the classic
cannabinoid tetrad battery; 2. Evaluate the utility of anhedonia as a measure of spontaneous THC
withdrawal; and 3. determine the utility of the positive allosteric modulator ZCZ011 and its
enantiomers in attenuating THC withdrawal.
2. Methods
2.1 Animals
Adult male and female C57BL/6J mice (N=589) (The Jackson Laboratory; Bar Harbor, ME)
were group housed (4-5 per cage) in Polysulfone plastic cages with food and water available ad
libitum. Mice were housed in a single temperature (20-22°C) and humidity (50 ± 5%) controlled
room. Mice were kept on a 12:12 h light/dark cycle and were randomly assigned to each
treatment group, such that each cage contained mice from at least two different treatment groups
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(e.g., no cage contained only AB-FUBINACA-treated mice). Experiments that used male and
female mice were stratified by sex before random assignment. All experiments were carried out
by trained technicians who were blinded to treatment conditions. The Animal Care and Use
Committee at West Virginia University approved all experimental protocols prior to the start of
any experimental manipulation.

2.2 Drugs
The cannabinoid receptor agonists AB-FUBINACA, ∆9-THC, JWH-018, and the
selective CB1 receptor antagonist rimonabant (SR141716A) were generously provided by the
National Institute on Drug Abuse (NIDA) Drug Supply Program (Bethesda, MD). ZCZ011
was purchased from Axon Medchem (Reston, VA) or provided by a collaborator (Dai Lu,
Texas A&M College of Pharmacy) who also provided the ZCZ011 racemates. All drugs were
dissolved in a vehicle composed of 5% ethanol, 5% Kolliphor EL (Sigma-Aldrich, St. Louis,
MO), and 90% normal saline (Kinsey & Cole, 2013). All solutions were warmed to room
temperature before administration at a volume of 10 µl/g body mass.
2.2.1 Precipitated withdrawal paradigm: Mice were weighed daily and injected subcutaneously
(s.c.) with AB-FUBINACA (1 or 3 mg/kg) or vehicle every 12 h for 6 days, as described
previously (Falenski et al., 2010; Schlosburg et al., 2009; Trexler et al., 2018). On the sixth day,
all mice received a final injection of AB-FUBINACA or vehicle. After 30 min, mice received an
intraperitoneal (i.p.) injection of rimonabant (3 mg/kg) (Lichtman, Fisher, & Martin, 2001;
Trexler et al., 2018) to precipitate withdrawal. Control mice received a vehicle injection on test
day.
2.2.2 Spontaneous withdrawal paradigm: Mice were weighed daily and injected subcutaneously
(s.c.) with either THC (10 mg/kg) or vehicle every 12 h for 6 days. Behavioral assessment in the
anhedonia assay was conducted 36 h after the final injection.

2.3 Behavioral Assessments
2.3.1 Tetrad: The “Billy Martin tetrad” is a well characterized battery of four assays used to
evaluate the effects of cannabinoid agonists (Kinsey & Cole, 2013; Lichtman et al., 2001;
Schlosburg et al., 2010). It consists of: catalepsy, antinociception, core body temperature, and
locomotor assessment. Catalepsy was assessed by gently laying the forepaws of individual mice
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over bar 3 cm above the benchtop. Total latency to move one or both forepaws off the bar was
recorded, with a maximum cutoff of 60 s (Long et al., 2009). Antinociception was measured via
immersing the distal tip of the tail (i.e., the last 1 cm) into a 56°C water bath (Falenski et al.,
2010). Latency to remove the tail from the water was recorded, with a maximum cutoff of 10 s.
Hypothermia was assessed by taking rectal temperature using a micro probe thermocouple
thermometer designed for use with mice (BAT-12, Physitemp Instruments Inc., Clifton, NJ,
USA). Spontaneous locomotor activity was measured by placing individual mice into an empty
test chamber (30 cm W x 40 cm L x 16 cm H) fitted with an overhead video camera, and
locomotor activity was scored using ANY-maze video tracking software (Stoetling, Wool Dale,
IL) for 5 min. In cases where mice were repeatedly tested a modified tetrad was used which
includes only catalepsy, antinociception and hypothermia assessments, as mice habituate to
locomotor testing.

2.3.2 Somatic signs testing: Somatic signs of withdrawal were measured as described previously
(Trexler et al., 2018). Each mouse was placed into an empty, plastic test chamber (20 cm W x 20
cm L x 15 cm H) inside a sound-attenuating chamber outfitted with a fan and white LED
lighting. The apparatus had three clear sides and one mirrored side that faced a video camera to
allow for observation of behavior when the mouse faced away from the camera.
Mice were habituated to the test apparatus following final AB-FUBINACA or vehicle
injection for 30 min and were then removed and injected with rimonabant or vehicle, as
previously reported (Schlosburg et al., 2009). The boxes were cleaned between subjects using a
paper towel moistened with distilled water. Each mouse was then be placed back into the test
chambers and video recorded for 60 min.
Video files were deidentified and scored by a trained observer. A subset of videos were
scored by a second observer to ensure inter-rater reliability (r2= .97). The dependent variables
were incidences of paw tremors and head twitches (i.e., an incidence was scored for ‘paw
tremor’ when the behavior was observed, not for each individual motion). Incidences were
considered separate when either (1) another behavior occurred between the incidences, or (2)
there was at least 1 s between incidences (Schlosburg et al., 2009).
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2.3.3 Marble Burying Test: Marble burying was measured as previously described (Broekkamp,
Rijk, Joly-gelouin, & Lloyd, 1986; Trexler et al., 2018), with minor changes. Plastic test
chambers (30 cm W x 40 cm L x 16 cm H) filled with Teklad Aspen Sani-Chip (7090A; Envigo,
Indianapolis, IN) wood bedding (5 cm deep) were placed inside sound-attenuating chambers
outfitted with a fan and LED lighting. A 5 x 5 array of 25 clear glass marbles was laid across the
top of the leveled bedding. Each mouse was placed into the chamber and allowed to freely
explore for 20 min. At the end of the test, each mouse was quickly and carefully removed and the
number of unburied marbles (≥1/3 of the surface showing) was recorded then subtracted from the
25 total marbles. Marbles were counted by a trained individual. Locomotor activity was
simultaneously recorded for the duration of the test by a camera mounted on the top of the test
chamber. The video data was analyzed in real time using ANY-maze (Stoetling, Wool Dale, IL)
video tracking software.

2.3.4 Tail Suspension Test: The tail suspension test was run as previously described (Kinsey,
Bailey, Sheridan, Padgett, & Avitsur, 2007; Steru, Chermat, Thierry, & Siman, 1985). Mice were
suspended by the tail with adhesive tape from a horizontal bar placed approximately 40 cm
above the benchtop and video recorded for 6 min. The total time the mice actively struggled was
hand-scored using ANY-maze (Stoetling, Wool Dale, IL) video tracking software. Active
struggling was operationally defined as one or more legs kicking repeatedly within one second,
or arching of the spine, but not head movement.

2.3.5 Light/Dark Box: The light/dark box test was conducted as described previously (Crawley &
Goodwin, 1980). The apparatus consisted of two connected Plexiglas chambers, with a small
passage hole at floor level. The larger chamber (30 cm W x 40 cm L x 30 cm H) was open and
brightly lit by an overhead lamp, and the smaller chamber (30 cm W x 20 cm L x 30 cm H) was
covered and constructed using dark red Plexiglas. Each apparatus was placed within a sound
attenuating chamber outfitted with a fan and LED lighting. In addition, an infrared LED array
(IR3, C&M Vision Technologies Inc, Houston, TX), along with a video camera (Logitech HD
Pro Webcam C920) with the infrared filer removed, were used to visualize the mice. Each mouse
was placed in the brightly lit area of the apparatus and allowed to freely explore for 5 min.
Locomotor activity was analyzed in real time using ANY-maze software (Stoetling, Wool Dale,
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IL). The dependent variables are total time spent in the dark box, latency to enter the dark box,
time immobile, and total distance traveled.

2.3.6 Open field: The open field test was conducted as previously described (Bailey, Kinsey,
Padgett, Sheridan, & Leblebicioglu, 2009). The apparatus consisted of a (40 cm W x 40 cm L x
30 cm H) box made of black Plexiglas with a white floor. Testing was carried out in individual
sound attenuating chambers fitted with LED lighting, a fan, and an overhead video camera. Mice
were individually placed into each apparatus and allowed to explore for 10 min. The field was
divided evenly into 36 squares which were then divided into two zones: the perimeter, which was
the space within 6 cm of the wall, and the center, which was the remaining 28 x 28 cm area not
adjacent to the walls (Kinsey et al., 2007). Time spent in the center of the apparatus, distance
traveled, and time immobile were quantified in real time using ANY-maze software (Stoetling,
Wool Dale, IL).

Figure 2. Time line for novelty-induced hypophagia.
2.3.7 Novelty-induced hypophagia: Novelty-induced hypophagia testing was conducted as
previously described (Gamble-George et al., 2013), with minor changes. Mice were single
housed at least 7 days prior to training. Mice were trained to consume a mixture of 1:3 parts
sweetened condensed milk and distilled water under dim light from sipper tubes placed in the
home cage. Training took place for 3 days (Figure 2), or until each mouse achieved a threshold
of consuming at approximately 1ml of the sweetened condensed milk mixture, whichever was
longer.
15

Synthetic Cannabinoid Agonism and Positive Allosteric Modulation - Trexler
On the first test day, mice were randomly assigned and tested for 30 min in either the
home cage under dim light, or an aversive condition. The dim light condition was the same as the
training condition (i.e., 2 lux red light in home cage). The aversive condition consisted of a
novel, empty (i.e., no bedding) cage placed on a white floor and brightly lit (1348 lux). On the
second test day, mice were tested in the counterbalanced condition. Drug treatments were
constant across test days. The following day, each mouse was returned to the training condition
and tested again, but without drug. The dependent variable was the volume of sweetened
condensed milk consumed. The volume was quantified by subtracting the post-test mass of the
bottle from the pre-test mass. A drip control (i.e., a bottle placed in a dummy cage that was not
used for testing) was included with each test group to account to for leakage. The data presented
represent the total volume consumed, controlled for the drip control for that day.
(𝑚𝑎𝑠𝑠𝑝𝑟𝑒 − 𝑚𝑎𝑠𝑠𝑝𝑜𝑠𝑡 )𝑡𝑒𝑠𝑡 − (𝑚𝑎𝑠𝑠𝑝𝑟𝑒 − 𝑚𝑎𝑠𝑠𝑝𝑜𝑠𝑡 )𝑑𝑟𝑖𝑝 𝑐𝑜𝑛𝑡𝑟𝑜𝑙

2.3.8 Anhedonia: Anhedonia is a reduced response to a reinforcer, often modeled as decreased
drinking of a highly palatable substance. Training was identical to the training phase of noveltyinduced hypophagia. When used to evaluate withdrawal, mice were trained to consume the
sweetened condensed milk mixture for 3 days prior to drug administration and continued daily
training through the 6-day drug administration phase. On test day, each mouse was habituated to
the dim room 35 h following final drug injection and tested 1 h later. Volume of sweetened
condensed milk consumed was quantified, as in the novelty-induced hypophagia test.

2.4 Statistical analyses
For experiment 1, data were analyzed using a repeated measures analysis of variance (ANOVA)
with dose as the within subjects variable. For experiment 2a, precipitated withdrawal data were
analyzed using a one-way ANOVA. For the spontaneous THC withdrawal experiment, t tests
were used to evaluate differences at training day 3, dosing days and 36 h abstinence. For
experiment 3a, one-way ANOVAs were used, with the exception of novelty-induced hypophagia
data, which were analyzed using a mixed design with day as the within subjects variable and
drug treatment as the between subjects variable. For experiment 3b, marble burying and tail
suspension data were analyzed using 2x3 ANOVAs. All other studies in experiment 3b were
analyzed using one-way ANOVAs. Main or interaction effects were followed by Dunnet (e.g.,
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for dose-response curves, comparing to vehicle treatment) or Bonferonni post hoc tests, as
appropriate. Differences were considered statistically significant if p < 0.05.
3. Results
The experiments in this study were designed to evaluate both acute and chronic effects of
AB-FUBINACA, withdrawal from THC and attenuation of withdrawal from THC. Experiment 1
evaluated acute and chronic AB-FUBINACA in the tetrad battery of tests. Experiment 2
evaluated precipitated withdrawal from AB-FUBINACA. Finally, Experiment 3 evaluated the
effects of acute ZCZ011, a CB1 positive allosteric modulator, and both of its enantiomers, and
their ability attenuate the somatic signs of THC withdrawal.

3.1 Experiment 1: AB-FUBINACA induces classic cannabinoid effects. To evaluate the acute
effects of AB-FUBINACA, male and female mice were injected with AB-FUBINACA (0.1, 1, 2,
or 3 mg/kg) or vehicle 30 min prior to testing. AB-FUBINACA (3 mg/kg) increased latency in
both catalepsy [F(4,32)=6.6,p<.05; Fig. 3A] and tail immersion [F(3,35)=6.9,p<.05; Fig. 3B]
tests. Mice treated with AB-FUBINACA (2 or 3 mg/kg) had decreased body temperature
[F(34,35)=24.9,p<.05; Fig. 3C] and increased time immobile [F(4,35)=11.4,p<.05; Fig. 3D]. The
antinociceptive (30 min), cataleptic (1 h), and hypothermic (2 h) effects of AB-FUBINACA
abated quickly [Fig.3E-G], as compared with the same effects of THC (50 mg/kg).
In a separate experiment, male and female mice were dosed twice daily with ABFUBINACA (3 mg/kg) for 5 days and were tested daily in tetrad, to determine the degree to
which AB-FUBINACA tolerance develops. Mice repeatedly administered AB-FUBINACA
maintained increased latency in catalepsy [Main effect drug F(1,70)=31.8,p<.05;Fig. 4A]
antinociception [Main effect drug F(1,70)=15.3,p<.05;Fig. 4B], and hypothermia despite 5 days
of treatment [Main effect drug F(1,70)= 121.5,p<.05;Fig. 4C]. Similarly, when challenged with
THC (50 mg/kg), mice treated with AB-FUBINACA for 5 days did not exhibit cross tolerance in
catalepsy [p=.48; Fig. 4D], tail immersion [p=.87;Fig. 4E], or body temperature [p=.27;Fig. 4F].
In the final experiment, male and female mice were injected twice daily with ABFUBINACA (1 or 3 mg/kg) for 5 days. On the 6th day, mice were injected with AB-FUBINACA
and were injected with rimonabant 30 min later and were immediately tested in somatic signs of
withdrawal. When rimonabant was administered, AB-FUBINACA (1 mg/kg) treated mice
exhibited increased paw tremors [t(18)=3.8,p<.05;Fig. 4G] and head twitches
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[t(18)=3.0,p<.05;Fig.4H] compared to vehicle treated mice. Similarly, AB-FUBINACA (3
mg/kg) withdrawal increased both paw tremors [F(2,20)=9.7, p<.05;Fig.4I] and head twitches
[F(2,20)=4.3, p<.05;Fig.4J]. It is important to note that the rimonabant-precipitated somatic
signs of withdrawal from AB-FUBINACA are of a smaller magnitude than those elicited by
THC (10 or 50 mg/kg) or JWH-018 (1 mg/kg) withdrawal (Trexler et al., 2018).

3.2 Experiment 2: Spontaneous THC withdrawal does not affect feeding. Because gastric issues
are a commonly reported somatic sign of cannabinoid withdrawal, mice were trained to drink a
sweetened condensed milk mixture and were treated twice daily for 6 days with either JWH-018
(1 mg/kg) or vehicle. Withdrawal was precipitated with rimonabant (3 mg/kg). Acute JWH-018
depressed drinking [Main effect of JWH-018 F(1,28)=279.3,p<.05; Fig. 5A], which returned to
baseline levels by day 5 [p=.54], indicating tolerance had developed. Rimonabant, per se,
significantly decreased feeding in both JWH-018 and vehicle treated mice Main effect of
rimonabant F(1,28)=95.1, p<.05]. Thus, the spontaneous THC (10 or 50 mg/kg) withdrawal
model was used next. Both THC (10 mg/kg) and vehicle groups consumed the same baseline
(training day 3)volume of milk [p=.53; Fig. 5B] and THC-treated (10 mg/kg) mice returned to
baseline consumption levels before testing [p=.19], indicating that THC tolerance developed.
Mice were tested 12 and 36 h after the final THC (10 mg/kg) or vehicle injection. Both THC (10
mg/kg) and vehicle treated mice consumed the same amount on test day [p=.16], indicating that
spontaneous THC has no effect on drinking.
Mice in both the THC and vehicle treated groups showed decreased in consumption
following the injection of the first day of dosing. It is likely that this decrease was due to the
stress of being injected. In a follow up experiment, the same experimental design was used,
however, mice were injected with either vehicle or THC (50 mg/kg) twice daily. Mice were
habituated to injections during training and vehicle-treated mice did not exhibit the same
decrease in drinking on the first day of dosing. Again, THC treatment caused a decrease in
drinking initially [t(6)=6.2, p<.05; Fig. 5C], and again, consumption returned to baseline by the
5th day of dosing [p=.61]. As with THC (10 mg/kg), THC (50 mg/kg) spontaneous withdrawal
did not cause a decrease in consumption relative to baseline at 12h [p=.24] or 36h [p=.70]
abstinence. In this experiment, the vehicle treated mice had continually increasing consumption,
making comparison between vehicle- and THC (50 mg/kg)-treated mice on test days misleading.
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3.3 Experiment 3a: Acute ZCZ011 does not have anxiolytic or anxiogenic effects. Cannabinoid
orthosteric ligands, including THC, have anxiolytic properties. To determine possible anxiogenic
or anxiolytic effects of ZCZ011, behavior was tested in the marble burying, light/dark box, open
field, and novelty-induced hypophagia tests. Male mice were injected with ZCZ011 (2.5, 5, 10,
20, or 40 mg/kg) or vehicle 75 min prior to testing in marble burying. Treatment with ZCZ011
(40 mg/kg) decreased marbles buried [F(5,74)= 14.0, p<.05; Fig. 6A], but also increased
immobility [F(95,1273)=1.7, p<.05; Fig. 6B], indicating that ZCZ011-suppressed marble
burying may reflect a broader decrease in activity in the assay. The lowest tested doses of
ZCZ011 (i.e., 2.5 and 5 mg/kg) did not produce any effects and were excluded from the
following tests.
Male and female mice were injected with ZCZ011 (10, 20, or 40 mg/kg, i.p.) or vehicle
75 min prior to testing in Light/Dark box. ZCZ011 (40 mg/kg) increased time in the dark
compared to vehicle controls [F(3,44)=2.9, p<.05; Fig. 6C]. Similarly, mice treated with
ZCZ011 (40 mg/kg) had increased immobility in the light/dark box [F(3,44)= 9.3, p<.05; Fig.
6D]. In addition, male and female mice were injected with ZCZ011 (10, 20, or 40 mg/kg, i.p.) or
vehicle 75 min prior to testing in the Open field test. ZCZ011 (10, 20, or 40 mg/kg) did not affect
time spent in the center of the apparatus [p=.39; Fig. 6E] or time spent immobile [p=.66; Fig.
6F], but ZCZ011 (40 mg/kg) decreased number of rears [F(3,44)=3.5,p<.05;Fig. 6G].
Another group of male and female mice were trained to consume at least 1g of a
sweetened condensed milk mixture for 3 days prior to testing. Mice were injected with ZCZ011
(10, 20, or 40 mg/kg, i.p.) or vehicle 75 min prior to testing in either a dim light condition or an
aversive condition in the presence or absence of ZCZ011, then in the opposite condition after 24
h. Drug treatment did not change across days. All mice consumed less milk in the aversive
condition [F(5,290)= 61.36, p<.05; Fig. 6H], and ZCZ011 (10, 20 or 40 mg/kg) did not affect
volume consumed in the aversive condition [p=.78]. When retrained in the dim condition the
following day, when no drug was administered, all mice, regardless of treatment or condition
order, returned to baseline drinking levels [p=.99].
A separate group of male and female mice was injected with either of the ZCZ011
enantiomers, referred to here as “ZCZ011A” or “ZCZ011B”, and was tested in open field and
marble burying tests. Neither compound affected time in the center of the open field [p=.08;Fig.
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7A], time immobile in open field [p=.06;Fig 7B], or rearing (an exploratory behavior) in the
open field test [p=.79;Fig. 7C]. Neither enantiomer affected marbles buried [p=.20;Fig. 7D], but
ZCZ011A increased time immobile [F(2,33)=5.9,p<.05;Fig. 7E].

3.4 Experiment 3b: Somatic signs of THC withdrawal attenuated by ZCZ011. ZCZ011 (10 or 40
mg/kg) attenuates somatic signs of THC withdrawal (Trexler et al., 2019). To determine whether
ZCZ011 also attenuates withdrawal-induced changes in marble burying and tail suspension, mice
were subjected to the rimonabant-precipitated THC withdrawal paradigm and injected with
ZCZ011 (10 or 40 mg/kg) or vehicle 75 min prior to testing. ZCZ011 (10 or 40 mg/kg) did not
attenuate THC withdrawal-suppressed marble burying [F(2,42)=12.2,p<.05;Fig. 8A] or
withdrawal-induced struggling in the tail suspension test [Main effect THC
[F(1,42)=89.4,p<.05;Fig.8B]. As in Exp. 3.3, ZCZ011 alone (40 mg/kg) increased immobility in
marble burying [Main effect ZCZ011 [F (2,42)= 7.3,p<.05; Fig. 8C]. Surprisingly, but ZCZ011
(≥10 mg/kg) increased immobility in mice subjected to precipitated THC withdrawal.
To determine ZCZ011 dose-dependent effects on attenuating somatic signs of
withdrawal, mice were subjected to precipitated THC withdrawal, and injected with ZCZ011 (1,
3.33, or 10 mg/kg) or vehicle. ZCZ011 (10 mg/kg) reduced both paw tremors
[F(4,32)=6.8,p<.05;Fig.8D] and head twitches [F(4,32)=4.5,p<.05;Fig.8E]. Posts hoc analyses
revealed that ZCZ011 (3.33 mg/kg) attenuated head twitches but had no effect on paw tremors.
The ability of the two enantiomers of ZCZ011, i.e., ZCZ011A and ZCZ011B, to attenuate
precipitated THC withdrawal was evaluated. Mice were subjected with precipitated THC
withdrawal and treated with ZCZ011A or ZCZ011B (0.55, 1.66, or 5 mg/kg) or vehicle 75 min
prior to testing. Either ZCZ011A or ZCZ011B (5 mg/kg) attenuated paw tremors
[F(4,35)=16.7,p<.05;Fig.8F] and head twitches [F(4,35)=10.8,p<.05;Fig.8G]. Neither ZCZ011A
nor ZCZ011B (0.55 or 1.66 mg/kg) affected paw tremors [p=.28;Fig. 8H] or head twitches
[p=.20;Fig. 8I].
4. Discussion
The current project was designed to evaluate the acute and chronic effects of the synthetic
cannabinoid AB-FUBINACA. It also evaluated the development of tolerance to and withdrawal
from AB-FUBINACA. Additionally, sweetened condensed milk consumption was evaluated as a
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potential new assay of spontaneous THC withdrawal. Finally, the acute anxiolytic effects of
ZCZ011 and its enantiomers was probed and ZCZ011 and its enantiomers were further evaluated
as a method of attenuating precipitated THC withdrawal.
AB-FUBINACA produced classic cannabinoid effects, including catalepsy, antinociception, hypothermia, and hypolocomotion. Surprisingly, AB-FUBINACA has a
significantly shorter timecourse than THC and previous generation synthetic cannabinoids.
While a rapid onset, similar to the one observed here, has been reported previously, the tetrad
effects in the present study abated more quickly than previously reported (Banister, Moir, et al.,
2015; Kevin et al., 2017). It is plausible that the differences in observed effect timecourse and
magnitude are due to a species difference, as the previous studies were carried out in rats.
Regardless, the rapid onset and relatively short timecourse are similar to those seen with other
third-generation synthetic cannabinoids, including AB-CHMINACA delivered via inhalation
(Lefever et al., 2017). A likely mechanism for the relatively quick recovery from these
compounds is rapid metabolism. Previous studies have demonstrated that synthetic cannabinoids
tend to be rapidly metabolized, and that more or less potent metabolites remain in the organism
interacting with cannabinoid receptors (Brents et al., 2012). It has been further suggested that an
alternate route of administration (e.g., inhalation) may be a better model of synthetic cannabinoid
use because these compounds are generally administered in vapor (Lefever et al., 2017), which
most closely resembles intravenous administration with regard to speed of delivery to brain.
Moreover, the rapid timecourse of new generation drugs is even further accelerated in an inhaled
aerosol model (Lefever et al., 2017). Regardless, the relatively short timecourse of ABFUBINACA reported here is novel and evident following intraperitoneal administration.
The lack of tolerance to AB-FUBINACA in the current experiments is in some ways
surprising, as the dosing regimen is adequate to produce tolerance to both THC and other
synthetic cannabinoids, like WIN55-212 and JWH-018 (Aceto et al., 2001; Lichtman, Fisher, &
Martin, 2001; Schlosburg et al., 2009; Trexler et al., 2018). Additionally, AB-FUBINACA is a
full CB1 agonist with higher potency than THC (Hess et al., 2016; Wiley et al., 2015). Thus, we
expected tolerance to develop at the same rate, or perhaps even earlier, than with THC. However,
the rapid timecourse of AB-FUBINACA metabolism may render the current dosing paradigm
ineffective. Thus, it is plausible that, for tolerance to fully develop, mice must be dosed more
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frequently, or perhaps ideally administered continuously, for example via osmotic minipump.
But, such an approach has limited construct validity and does not reflect patterns of human
cannabinoid self-administration. Regardless, the small effect of precipitated AB-FUBINACA
withdrawal is not surprising, given the observed lack of tolerance in the tetrad battery. It was also
expected that, given its relatively higher potency, AB-FUBINACA withdrawal would be of the
same or perhaps larger magnitude than that of THC, but the observed withdrawal effects, while
statistically significant, were relatively minor. This issue may also be resolved by adjusting the
dosing regimen as outlined above, or perhaps other behavioral assays will reveal subtleties in
AB-FUBINACA withdrawal that were not detectable with the present assays.
Generally, AB-FUBINACA exhibited cannabimimetic effects in the tetrad battery of
assays, but has a much faster time course. To further explore the effects of AB-FUBINACA,
future studies should include components evaluating brain, plasma, or urine analysis for
metabolites of the drug over time. I anticipate that AB-FUBINACA is rapidly metabolized in
vivo, and that patterns of brain levels will mirror those of the behavioral assays reported on here.
Additional studies that challenge the effects of AB-FUBINACA, for example with the CB1
inverse agonist rimonabant, will also be useful in determining whether all of the effects observed
were CB1 mediated, or if AB-FUBINACA is acting, at least in part, through cannabinoid
receptor independent mechanisms.
Due to the small effect of precipitated AB-FUBINACA withdrawal, THC was used to
pilot the possible effects of cannabinoid withdrawal on sweetened condensed milk consumption.
We evaluated spontaneous THC withdrawal effects on sweetened condensed milk consumption,
a common anhedonia model. We chose a spontaneous withdrawal paradigm, because pilot data
(Fig 5A) indicated that rimonabant, per se, suppresses drinking. In the present study,
spontaneous THC withdrawal was evaluated 36 h after the final THC injection. This 36 h
timepoint was selected because we have previously reported “peak” withdrawal signs at 36 h
THC abstinence (Trexler et al., 2018). I hypothesized that mice would exhibit decreased
sweetened condensed milk consumption during spontaneous withdrawal, but this effect was not
observed. Given the lack of an effect of THC withdrawal, we chose not to test spontaneous ABFUBINACA withdrawal in this model. Because somatic signs of precipitated AB-FUBINACA
withdrawal (i.e., Exp 2a) were of surprisingly small magnitude, and that effects of spontaneous
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withdrawal are typically of a smaller magnitude than precipitated withdrawal models (Aceto et
al., 2001;Trexler, Eckard, & Kinsey, 2019; Trexler et al., 2018), we concluded that spontaneous
AB-FUBINACA withdrawal effects on sweetened condensed milk consumption are unlikely to
be observed.
In addition to measuring feeding behavior, sweetened milk drinking was chosen in this
study because of its use in evaluating depressive-like effects (i.e., anhedonia), which humans
frequently report as a symptom of cannabis withdrawal (American Psychiatric Association,
2013). Because of the differences in type of symptomology (i.e, somatic symptoms versus
emotionality-related symptoms), it is plausible that the onset of different behavioral changes
occur at different times. For example, we have previously reported that both precipitated and
spontaneous THC withdrawal increase struggling in the tail suspension test (Trexler et al., 2018).
Coincident with spontaneous somatic withdrawal signs, the increase in struggling is evident at 36
h abstinence. Thus, although we did not observe altered drinking at 12 or 36 h abstinence,
expending the number of time points of sampling may reveal a withdrawal time course in this
assay that differs from other models. Another approach would be to increase THC dosing,
perhaps to 50 mg/kg twice daily, with the goal of increasing withdrawal effects. Although we
have not observed differences between 10 and 50 mg/kg THC in somatic signs of withdrawal or
tail suspension tests (Trexler et al., 2018), it is plausible that feeding is sensitive to such
differences in dosing.
Acute ZCZ011 was evaluated in several anxiety-related assays because increased activity
of the endocannabinoid system has anxiolytic effects (Kinsey, O’Neal, Long, Cravatt, &
Lichtman, 2011; Moreira, Grieb, & Lutz, 2009). ZCZ011 decreased marble burying and
decreased rearing in the open field test, which would typically be interpreted as an anxiolytic
drug profile. In the light/dark box test, however, ZCZ011 increased time spent in the dark, which
would typically be interpreted as an anxiogenic effect. But, the same dose of ZCZ011 (40 mg/kg)
also elicited locomotor effects in both the marble burying and light/dark box tests, indicating that
the decrease in marbles buried and increased time in the dark were likely due to sedative effects.
This effect contrasts with findings showing the same dose of ZCZ011 does not produce
locomotor suppression the spontaneous locomotor test (Ignatowska-Jankowska et al., 2015;
Trexler et al., 2019). The light/dark box test relies on creating a conflict paradigm to evaluate
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anxiety-like behavior (Crawley, 2007) and the marble burying test also been implicated as a
stress-inducing paradigm (Abraham et al., 2018), so it is plausible that the locomotor effects of
ZCZ011 are only observed in stressful or aversive conditions, which would not include the
apparatus used in a spontaneous locomotor assessment. Thus, the assay dependent locomotor
effects observed may be compounded by stress responsiveness.
Both enantiomers of ZCZ011, ZCZ011A and ZCZ011B, were evaluated independently in
marble burying and open field assays. ZCZ011A caused decreased locomotion in the marble
burying task, but did not cause a statistically significant reduction in number of marbles buried.
We found no effects of either enantiomer in open field, which is consistent with the lack of effect
of ZCZ011 in open field. The locomotor deficits observed in the marble burying and light/dark
box tests are the result of ZCZ011A, rather than ZCZ011B, as evidenced by the locomotor
deficit associated with ZCZ011A in the marble burying test. Future studies evaluating dose
dependent effects of the individual enantiomers and evaluation in the light/dark box assay are
needed to determine relative contributions of each enantiomer.
Precipitated THC withdrawal was challenged with ZCZ011 in the marble burying and tail
suspension tests. Interestingly, precipitated withdrawal-depressed marble burying and increased
tail suspension struggling were not attenuated by ZCZ011 (10 and 40 mg/kg), which is similar to
previous findings using the MAGL inhibitor JZL184 (Trexler et al., 2018), which increases brain
levels of 2-AG by preventing its catabolism. Both ZCZ011 and JZL184 attenuate both
precipitated and spontaneous somatic signs of withdrawal, but neither drug reverses withdrawaldepressed marble burying or withdrawal-induced increases in struggling in the tail suspension
test. Plasma levels of the stress hormone corticosterone increase during THC withdrawal, and the
endocannabinoid system and stress circuitry are closely related (Hill & Gorzalka, 2005; Oliva et
al., 2004; Patel, Roelke, Rademacher, & Hillard, 2005; Trexler et al., 2018). Thus, the decrease
in marble burying and increase in struggling during THC withdrawal may be related to altered
regulation of the hypothalamic-pituitary-adrenal (HPA) axis stress circuit caused by repeated
CB1 activation. Interestingly, these effects are not attenuated by administration of a
glucocorticoid antagonist, mifepristone, or a β-adrenergic antagonist, propranolol, indicating the
effect is likely not mediated through those mechanisms (Trexler et al., 2018). Thus, future
studies should target corticotrophin releasing factor as a stress mechanism that mediates the
emotionality-related behavioral effects of cannabinoid withdrawal.
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ZCZ011 attenuated somatic signs of THC withdrawal in a dose dependent manner. The
lowest dose tested, 1 mg/kg, did not attenuate paw tremors or head twitches, and the moderate
dose, 3 mg/kg, attenuated head twitches, but not paw tremors, and the highest dose tested, 10
mg/kg, attenuated both paw tremors and head twitches, as previously published (Trexler et al.,
2019). It is noteworthy that, no locomotor effects of 10 mg/kg ZCZ011 are observed in any
assays, which rules out possible sedative confounds. CB1 positive allosteric modulation is a
relatively new area, but several PAMs have already shown demonstrated their anti-nociceptive,
anti-inflammatory, and gastroprotective properties (Ignatowska-Jankowska et al., 2015; Slivicki
et al., 2017; Trexler et al., 2019), so this approach has been fruitful, albeit using different
endogenous target receptor systems. Further, the finding that either enantiomer of ZCZ011
attenuates somatic signs of withdrawal is promising. Moreover, ZCZ011B not only attenuates
withdrawal, but does so with no locomotor effects of its own. Taken together, the present data
indicate that ZCZ011B, or a novel compound with similar properties, shows early promise as an
option for development as a therapeutic agent to treat cannabis use disorder.

5. Conclusion
The present studies revealed that AB-FUBINACA, a third-generation synthetic
cannabinoid, has cannabimimetic effects that abate much more rapidly than the traditional
phytocannabinoid, THC. Future studies into its metabolism will help to further understand the
differences between AB-FUBINACA and THC. As human use of synthetic cannabinoids
continues it will be increasingly important to use the information gained from experimental study
to inform treatments for synthetic cannabinoids. Though spontaneous THC withdrawal is reliably
observed in somatic and tail suspension models, it was undetectable in an anhedonia model. The
exploration of additional timepoints may reveal that in the anhedonia model, THC withdrawal
peaks at a different time. Finally, ZCZ011 has few acute effects on its own, and the effects it
does have are likely driven by sedative effects, which appear to be caused entirely by one
enantiomer, ZCZ011A. Further, ZCZ011 and each of its enantiomers attenuate THC withdrawal
in a somatic model at doses that do not produce sedative effects. ZCZ011B may also be a
therapeutic agent due to its ability to attenuate withdrawal and its lack of acute locomotor effects.
Regardless of the individual contributions of either enantiomer, these data provide proof-of-
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concept that CB1 positive allosteric modulation is a viable strategy for reducing cannabis use
disorder.
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Figure 3. AB-FUBINACA has short-acting cannabinoid effects. Male and female mice were
treated with AB-FUBINACA (0.1-3 mg/kg, i.p.) 30 min prior to testing in the tetrad battery. ABFUBINACA induced catalepsy (A) antinociception (B), hypothermia (C), and hypolocomotion
(D), consistent with established cannabinoid effects. A second group of male and female mice
was injected with AB-FUBINACA (3 mg/kg, i.p.) or THC (50 mg/kg) and tested repeatedly in a
modified tetrad battery. The effects of AB-FUBINACA abated more quickly than the effects of
THC in catalepsy (E), antinociception (F), and hypothermia (G). Data represent mean ± SEM
(n=8[4m/4f]/group);*p<.05 v. vehicle or baseline.

39

Synthetic Cannabinoid Agonism and Positive Allosteric Modulation - Trexler

Figure 4. Chronic effects of AB-FUBINACA. Mice were treated with twice daily with ABFUBINACA (3 mg/kg, i.p.) or vehicle for 5 days. Mice were assessed in a modified tetrad
battery every morning approximately 30 min after injections. Mice treated with AB-FUBINACA
did not develop tolerance to its effects in catalepsy (A), tail immersion (B), or body temperature
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(C). On the 6th day, mice were baselined, then injected with THC (50 mg/k, i.p.) to evaluate
cross-tolerance. Mice treated with AB-FUBINACA showed no cross tolerance to THC in
catalepsy (D), antinociception (E), or hypothermia (F). To evaluate precipitated withdrawal from
AB-FUBINACA, separate groups of mice were treated with AB-FUBINACA (1 or 3 mg/kg, i.p.)
twice daily for 6 days. On the 6th day, mice were injected with rimonabant and then evaluated for
somatic signs of withdrawal. AB-FUBINACA (1 or 3 mg/kg) increased paw tremors (G & I) and
head twitches (H & J). Data represent mean ± SEM (n=8-10 [4-5m/4-5f] /group); *p<.05 v.
vehicle or baseline; #p<.05 v. AB-FUB/vehicle.
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Figure 5. Spontaneous THC withdrawal had no effect on feeding. Mice were treated twice daily
with JWH-018 (1 mg/kg) or vehicle for 6 days and were then subjected to precipitated
withdrawal. Rimonabant decreased drinking in both JWH-018 and vehicle treated mice (A).
Mice were treated with twice daily with THC (10 mg/kg, i.p.) or vehicle for 5 days. Mice were
assessed an anhedonia assay 12 h and 36 h after the final THC or vehicle injection
(B). No effect of spontaneous THC (10 mg/kg) withdrawal was observed. Similarly, mice treated
for 5 days with THC (50 mg/kg, i.p.) or vehicle did not show spontaneous withdrawal at 12h or
36h (C). Data represent mean ± SEM (n=8 [4m/4f]/group) *p<.05 v. vehicle control; #p<.05 v.
own baseline (Training 3).
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Figure 6. Acute ZCZ011 decreased marble burying and increased immobility in a subset of tests.
Separate groups of mice were treated with acute ZCZ011 (2.5-40 mg/kg, i.p.) or vehicle 75 min
prior to testing. Mice treated with ZCZ011 (40 mg/kg) buried fewer marbles (A) and spent more
time immobile in marble burying (B). Mice treated with ZCZ011 (40 mg/kg) spent more time in
the dark (C) and more time immobile in the light/dark box test (D). Mice treated with ZCZ011
(40 mg/kg) did not differ in time spent in the center of the open field (E) or time spent immobile
(F) but reared less (G). ZCZ011 did not affect amount consumed in novelty-induced hypophagia
(H). Data represent mean ± SEM (n=12-16[6-8m/6-8f]/group); *p<.05 v. vehicle or baseline.

43

Synthetic Cannabinoid Agonism and Positive Allosteric Modulation - Trexler

Figure 7. Acute effects of ZCZ011 enantiomers. Mice were treated with either acute ZCZ011A
(20 mg/kg, i.p.), ZCZ011B (20 mg/kg, i.p.) or vehicle 75 min prior to testing .Neither ZCZ011A
nor ZCZ011B affected time in the center of the open field (A), time immobile during open field
(B), or rearing (C). Neither ZCZ011A nor ZCZ011B affected marbled buried (D), but ZCZ011A
increased time spent immobile in marble burying (E). Data represent mean ± SEM
(n=12[6m/6f]/group); *p<.05 v. vehicle or baseline.
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Figure 8. ZCZ011 attenuates somatic signs of precipitated THC withdrawal. Separate groups of
mice were treated with THC (10 mg/kg, i.p.) or vehicle twice daily for 6 days. On the 6 th day,
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mice were injected with ZCZ011 (1-40 mg/kg) or vehicle, then injected with rimonabant and
then evaluated in marble burying and tail suspension or somatic signs of withdrawal. ZCZ011
(10 or 40 mg/kg) did not attenuate withdrawal-induced changes in marble burying (A) or tail
suspension test (C). ZCZ011 (10 or 40 mg/kg increased immobility in mice subjected to
withdrawal in marble burying (B). ZCZ011 (10 mg/kg) attenuated paw tremors (D) and head
twitches (E). In a second set of experiments, mice were treated on the 6 th day with ZCZ011A
(0.55-5 mg/kg, i.p.), ZCZ011B (0.55-5 mg/kg, i.p.) or vehicle, then injected with rimonabant and
evaluated for somatic signs of THC withdrawal. Both ZCZ011A (5 mg/kg) and ZCZ011B (5
mg/kg) attenuated paw tremors (F) and head twitches (G). Neither ZCZ011A (0.55 or 1.66
mg/kg) nor ZCZ011B (0.55 or 1.6 mg/kg) attenuated paw tremors (H) or head twitches (I). Data
represent mean ± SEM (n=8 [4m/4f]/group); *p<.05 v. vehicle or baseline, #p<.05 v.
THC/Vehicle.
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Appendix A. Analysis of covariance (ANCOVA) for experiments 2, 3a, and 3b.
To standardize drinking across days in the anhedonia assays in experiment 2, an analysis
of covariance (ANCOVA) was conducted using baseline as a covariate. Even when baseline
consumption was considered, there was no difference in consumption between THC (10 mg/kg)
and vehicle treated mice at 12h [p=.80] or 36h [p=.76]. When baseline was used as a covariate
for THC (50 mg/kg) withdrawal, again, at 12h there was no difference in consumption [p=.07].
Interestingly, THC (50 mg/kg) withdrawal caused a significant decrease in consumption at 36h
when analyzed using ANCOVA [F(1,11)=9.07, p<.05].
I speculated that the decrease in marbles buried and increase in time spent in the dark
observed in experiment 3a following ZCZ011 administration was due to increased immobility.
To determine whether immobility affected marbles buried and time spent in the dark during
light/dark box, separate ANCOVAs were done using time immobile as the covariate. Indeed,
when analyzed with ANCOVA, the initial decrease in marbles buried is no longer significant
[p=.17], nor is the increase in time spent in the dark during the light/dark box test [p=.08]. This
indicates that the observed changes were related to increased immobility.
Finally, in experiment 3b, I speculated that the decrease in marbles buried in ZCZ011
treated mice was due to increased immobility. Again, an ANCOVA was done to determine
whether this was the case and again, the decrease in marbles buried was no longer significant
when immobility was taken into account as a covariate [p=.86].
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Appendix B. Table of post hoc analyses. The post hoc analyses completed for the present experiments are listed in the
table below. Bold indicates significance.
Experiment 1: AB-FUBINACA induces classic cannabinoid effects
Acute tetrad - compared via Dunnett's against
vehicle control

Repeated dosing tetrad - compared via t-test
against vehicle with Bonferroni correction
(significant if p< 0.01); df:14

Dose (mg/kg)
0.1
1
2
3

mean
difference
-0.234
-0.234
1.952
11.401

critical
difference
6.331
6.331
6.553
6.838

Tail immersion

0.1
1
2
3

-0.679
2.926
3.698
6.349

3.94
3.94
3.94
3.94

Body Temperature

0.1
1
2
3

-0.2
-.537
-4.15
-5.75

-1.92
-1.92
-1.92
-1.92

Locomotor

0.1
1
2
3

12.988
39.338
104.05
163.263

73.408
73.408
73.408
73.408

Group
Day 1
Day 2
Day 3
Day 4
Day 5

t value
1.296
7.164
2.424
4.105
3.514

p value
0.2166
<.0001
0.0295
0.0011
0.0034

Day 1
Day 2
Day 3
Day 4

2.986
2.146
1.998
3.08

0.0098
0.0499
0.0655
0.0081

Catalepsy

Catalepsy

Tail immersion
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Body Temperature

AB-FUBINACA (3 mg/kg) precipitated
withdrawal - compared via Bonferroni (significant
if p< 0.0167)

Paw tremors

Head twitches

AB-FUBINACA and THC tetrad timecourse compared via Dunnett against baseline
Catalepsy

Tail immersion

Day 5

2.292

0.0379

Day 1
Day 2
Day 3
Day 4
Day 5

-10.413
-12.6
-3.98
-3.297
-4.276

<.0001
<.0001
0.0014
0.0053
0.0008

Comparison
Vehicle v. AB-F
Vehicle v. AB-F/Rim
AB-F v. AB-F/Rim

Mean
difference
0.625
-5.518
-6.143

critical
difference
3.839
3.974
3.974

p value
0.6751
0.0017
0.0006

Vehicle v. AB-F
Vehicle v. AB-F/Rim
AB-F v. AB-F/Rim

0.25
-2.464
-2.714

2.652
2.652
2.652

.8.14
0.0248
0.0146

AB-FUBINACA
Mean
Critical
Difference
Difference
0
18.715
36.881
18.715
25.327
18.715
14.046
18.715
0.748
18.715
0.564
18.715
0
18.715
0
18.715
0
18.715
0
18.715

Mean
Difference
0
13.755
16.585
17.558
14.134
8.129
0
0.851
0
0

THC
Critical
Difference
15.823
15.823
15.823
15.823
15.823
15.823
15.823
15.823
15.823
15.823

0.643
5.248
6.309

3.082
3.082
3.082

Timepoint
0 min
15 min
30 min
1h
2h
4h
8h
12h
24h
48h
5 min
20 min
35 min

1.357
5.279
6.731

2.897
2.897
2.897
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Body Temperature

1h
2h
4h
8h
12h
24h
48h

2.865
1.769
0.549
0.786
0.226
0.63
0.042

2.897
2.897
2.897
2.897
2.897
2.897
2.897

5.978
7.365
8.053
5.698
3.569
-0.153
-0.314

3.082
3.082
3.082
3.082
3.082
3.082
3.082

10 min
25 min
40 min
1h
2h
4h
8h
12h
24h
48h

-2.013
-6.913
-6.775
-5.163
-2.125
-0.587
-0.188
0.188
-0.35
-0.125

1.751
1.751
1.751
1.751
1.751
1.751
1.751
1.751
1.751
1.751

-1.088
-5.675
-6.45
-6.838
-7.137
-6.213
-3.913
-2.45
-0.35
-0.1

1.185
1.185
1.185
1.185
1.185
1.185
1.185
1.185
1.185
1.185

Timepoint
Training day 1
Training day 2
Training day 3
Dosing day 1
Dosing day 2
Dosing day 3
Dosing day 4
Dosing day 5
Test day
Reversal day

f value
0.088
0.507
0
279.336
52.732
19.012
7.002
2.69
0.057
8.114

p value
0.7685
0.4822
0.9994
<.0001
<.0001
0.0002
0.0132
0.1122
0.8137
0.0081

Training day 1
Training day 2

0.016
0.082

0.9004
0.7766

Experiment 2: Spontaneous THC withdrawal does not affect feeding
JWH-018 spontaneous withdrawal - compared via
ANOVA with Bonferroni correction (significant if
p<0.005); df:1,28

JWH-018 main effects

Rimonabant main
effects
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Interactions

THC spontaneous withdrawal - compared via t
test with Bonferroni correction (significant if
p<0.005); df:14

THC (10 mg/kg)

THC (50 mg/kg)

Training day 3
Dosing day 1
Dosing day 2
Dosing day 3
Dosing day 4
Dosing day 5
Test day
Reversal day

0.195
0.463
0.31
1.023
0.01
1.189
95.051
0.358

0.6626
0.5018
0.5823
0.3205
0.9204
0.2848
<.0001
0.5545

Training day 1
Training day 2
Training day 3
Dosing day 1
Dosing day 2
Dosing day 3
Dosing day 4
Dosing day 5
Test day
Reversal day

2.221
0.48
0.686
0.554
5.39
0.011
0.269
0.052
0.152
0.401

0.1474
0.494
0.4146
0.4629
0.0277
0.9188
0.6081
0.537
0.6999
0.5319

Timepoint
Training day 1
Training day 2
Training day 3
Dosing day 1
Dosing day 2
Dosing day 3
Dosing day 4
Dosing day 5
12 h abstinence
36h abstinence

t value
0.638
0.831
0.652
2.693
2.408
2.855
2.825
1.386
0.485
0.903

p value
0.5337
0.199
0.5252
0.0184
0.0304
0.0127
0.0135
0.1891
0.652
0.3817

Timepoint
Training day 1

t value
-0.168

p value
0.8693
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Training day 2
Training day 3
Dosing day 1
Dosing day 2
Dosing day 3
Dosing day 4
Dosing day 5
12 h abstinence
36h abstinence

-0.547
-1.378
5.905
-3.196
-4.134
-3.67
-5.355
0.115
-0.159

0.5929
0.1915
<.0001
0.0065
0.001
0.0025
0.0001
0.9099
0.8758

Mean
Difference
4.57
3.07
1.373
-3.192
-10.513

Critical
Difference
4.808
5.276
4.593
4.593
4.808

-0.636
0.849
0.589
4.921
21.009

5.618
5.815
5.308
5.308
5.308

Mean
Difference
9.3
21.342
45.025

Critical
Difference
39.072
39.072
39.072

3.05
25.675
71.925

37.252
37.252
37.252

3.3 Experiment 3a: Acute ZCZ011 does not have anxiolytic or anxiogenic effects
ZCZ011 Marble burying dose response compared via Dunnett against vehicle

Marble burying

Immobility

ZCZ011 Light/Dark Box dose response compared via Dunnett against vehicle

Time in dark

Immobility

Dose (mg/kg)
2.5
5
10
20
40
2.5
5
10
20
40

Dose (mg/kg)
10
20
40
10
20
40
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ZCZ011 Open field dose response - compared via
Dunnett against vehicle

Number of rears

ZCZ011 enantiomer marble burying immobility compared via Dunnett against 1 min

Dose (mg/kg)
10
20
40

Mean
Difference
1.417
-3.5
-13.917

Critical
Difference
12.784
12.784
12.784

Minute (out of 20)
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Mean
Difference
2.15
0.7
3.763
4.15
7.35
8.138
11.213
10.975
14.363
13.488
18.988
11.387
27.775
32.25
30.45
22.438
33.2
35.425
44.575

ZCZ011 A
Critical
Difference
16.016
16.016
16.016
16.016
16.016
16.016
16.016
16.016
16.016
16.016
16.016
16.016
16.016
16.016
16.016
16.016
16.016
16.016
16.016

t value
3.466
6.311

p value
0.0038
<.0001

Mean
Difference
2.925
0.825
4.7
2.175
4.725
1.688
4.2
3.65
4.388
4.725
6.188
4.95
8.262
4.675
3.15
4.463
9.5
11.35
14.488

ZCZ011 B
Critical
Difference
9.115
9.115
9.115
9.115
9.115
9.115
9.115
9.115
9.115
9.115
9.115
9.115
9.115
9.115
9.115
9.115
9.115
9.115
9.115

3.4 Experiment 3b: Somatic signs of THC withdrawal attenuated by
ZCZ011
THC precipitated withdrawal with ZCZ011
attenuation in marble burying - compared via

Marble burying

Comparison
Vehicle v. THC
Vehicle v. THC+ZCZ 10

53

Synthetic Cannabinoid Agonism and Positive Allosteric Modulation - Trexler
planned t tests with Bonferroni correction
(significant if p<0.0125); df:14

THC precipitated withdrawal with ZCZ011
attenuation in somatic signs - compared via
Bonferroni (significant if p<0.005)

Vehicle v. THC+ZCZ 40

Paw tremors

Head twitches

THC precipitated withdrawal with ZCZ011
enantiomer (5 mg/kg only) attenuation in somatic
signs - compared via Bonferroni (significant if
p<0.005)

Paw tremors

Comparison
Vehicle v. THC
Vehicle v. THC+ZCZ 1
Vehicle v. THC+ZCZ 3.33
Vehicle v. THC+ZCZ 10
THC v. THC+ZCZ 1
THC v. THC+ZCZ 3.33
THC v. THC+ZCZ 10
THC+ZCZ 1 v. THC+ZCZ
3.33
THC+ZCZ 1 v. THC+ZCZ 10
THC+ZCZ 3.33 v. THC+ZCZ
10
Vehicle v. THC
Vehicle v. THC+ZCZ 1
Vehicle v. THC+ZCZ 3.33
Vehicle v. THC+ZCZ 10
THC v. THC+ZCZ 1
THC v. THC+ZCZ 3.33
THC v. THC+ZCZ 10
THC+ZCZ 1 v. THC+ZCZ
3.33
THC+ZCZ 1 v. THC+ZCZ 10
THC+ZCZ 3.33 v. THC+ZCZ
10

Comparison
Vehicle v. THC
Vehicle v. THC+ZCZ 10
Vehicle v. THC+ZCZ A
Vehicle v. THC+ZCZ B

0.858

0.4051

Mean
difference
-46.857
-36.696
37.286
-12.696
10.161
9.571
34.161

critical
difference
32.277
31.252
32.277
31.252
31.252
32.277
31.252

p value
0.0001
0.0012
0.015
0.2296
0.3343
0.378
0.0024

-0.589
24

31.252
30.192

0.975
0.0226

24.589

31.252

0.0239

-7.286
-5.625
-3.286
-2.875
1.661
4
4.411

5.652
5.473
5.652
5.473
5.473
5.652
5.473

0.0005
0.004
0.0892
0.123
0.3671
0.0406
0.0209

2.339
2.75

5.473
5.287

0.2067
0.1267

0.411

5.473

0.8824

Mean
difference
-38.625
-1.875
-10.375
-8.375

critical
difference
16.135
16.135
16.135
16.135

p value
<.0001
0.7298
0.0622
0.1289
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Head twitches

THC v. THC+ZCZ 10
THC v. THC+ZCZ A
THC v. THC+ZCZ B
THC+ZCZ 10 v. THC+ZCZ A
THC+ZCZ 10 v. THC+ZCZ B
THC+ZCZ A v. THC+ZCZ B

36.75
28.25
30.25
-8.5
-6.5
2

16.135
16.135
16.135
16.135
16.135
16.135

<.0001
<.0001
<.0001
0.1235
0.2355
0.7126

Vehicle v. THC
Vehicle v. THC+ZCZ 10
Vehicle v. THC+ZCZ A
Vehicle v. THC+ZCZ B
THC v. THC+ZCZ 10
THC v. THC+ZCZ A
THC v. THC+ZCZ B
THC+ZCZ 10 v. THC+ZCZ A
THC+ZCZ 10 v. THC+ZCZ B
THC+ZCZ A v. THC+ZCZ B

-5.375
-0.125
-0.875
-1.625
5.25
4.5
3.75
-0.75
-1.5
-0.75

2.854
2.854
2.854
2.854
2.854
2.854
2.854
2.854
2.854
2.854

<.0001
0.8963
0.3645
0.0968
<.0001
<.0001
0.0004
0.4363
0.1243
0.4363
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